Ask VialBase
Narrative review · PMID 41966639

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — VialBase Research

AOD-9604 among unapproved peptides marketed directly to patients

Last updated · 2026 · Mendias CL, Awan TM · Sports Med
Key findings
  • AOD-9604 among unapproved peptides marketed directly to patients
  • Favorable tissue repair and metabolic outcomes in animal models
  • Rigorous human safety data scarce for most unapproved peptides
  • Potential for serious harm from unregulated supply chain
  • Framework provided for navigating peptide use in sports medicine

AOD-9604 in Sports Medicine Peptide Review (PMID: 41966639)

Review Scope

  • Narrative review of both approved and unapproved peptide therapies
  • Covers AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin, TB4/TB-500
  • Focus on musculoskeletal injuries and athletic performance

Key Points on AOD-9604

  • Classified as unapproved peptide marketed directly to patients
  • Animal models show favorable metabolic and tissue repair outcomes
  • Phase IIb human trial conducted (safety confirmed, modest efficacy)
  • Lack of Phase III / rigorous human data
  • “Gray market” supply chain raises contamination and quality concerns

Regulatory Framework

  • The review provides a framework for clinicians navigating peptide use
  • Distinguishes between approved (tesamorelin, sermorelin) and unapproved compounds
  • Emphasizes that preclinical promise does not equal clinical validation

Relevance

Important context for AOD-9604 use: while safety data from Phase IIb is reassuring, the compound remains unapproved and lacks definitive efficacy data from Phase III trials. Supply chain quality is a significant practical concern.

See Also

View on PubMed · PMID 41966639 →